

PROLIGHT RECEIVES NOTICE OF ALLOWANCE FOR MICROFLEX PATENT

Prolight has received notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application concerning the analytical device and reaction chamber for the company's point-of-care system MicroFlex, in development by Prolight's partner TTP (The Technology Partnership plc).

The notice of allowance from USPTO means that the patent application is intended to be approved in the USA after certain formal steps are completed. Once granted, the patent will be in effect until May 2040.

The patent, once granted, provides protection for the unique technical composition of the MicroFlex's analytical device and reaction chamber.

"The patent is a testament to the technological height of MicroFlex. We are certain that it will add to MicroFlex's competitive position and that TTP will make good use of it," said Ulf Bladin, CEO of Prolight.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

[Prolight receives notice of allowance for MicroFlex patent](#)